Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD outside of Canada and the US) ...

Health Canada has approved MSD's anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating adults with ...

MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial.

MSD and Eisai have announced mixed results from a Phase III trial of a Keytruda (pembrolizumab) combination as a first-line treatment for patients with metastatic human epidermal growth factor ...

MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable (MSS ...

the two drugs account for more than half of all sales at MSD which, in North America, is known as Merck. That brings its own concerns, not least the expiry of key US patents for Keytruda in 2028 ...

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...

Keytruda and Lenvima with chemotherapy improved progression-free survival and objective response rate but not overall survival in HER2-negative gastroesophageal adenocarcinoma. The safety profile of ...

A global phase 3 trial is evaluating ASP-1929 photoimmunotherapy with Keytruda for recurrent HNSCC, involving around 400 patients. ASP-1929, an antibody-dye conjugate targeting EGFR, is activated by ...

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...